|
134
|
322
|
6f8rA |
Crystal structure of the pde4d catalytic domain in complex with gebr-54 |
|
134
|
322
|
6f8uA |
Crystal structure of the pde4d catalytic domain in complex with gebr-20b |
|
135
|
328
|
6f8tA |
Crystal structure of the pde4d catalytic domain in complex with gebr-4a |
|
137
|
322
|
6f8xA |
Crystal structure of the pde4d catalytic domain in complex with gebr-26g |
|
130
|
328
|
6f6uA |
Crystal structure of the pde4d catalytic domain in complex with gebr-7b |
|
132
|
322
|
6f8wA |
Crystal structure of the pde4d catalytic domain in complex with gebr-18a |
|
134
|
327
|
6f8vA |
Crystal structure of the pde4d catalytic domain in complex with gebr-18b |
|
145
|
353
|
6bojA |
Crystal structure of the pde4d catalytic domain and ucr2 regulatory helix with bpn5004 |
|
136
|
358
|
3wd9A |
Crystal structure of phosphodiesterase 4b in complex with compound 10f |
|
131
|
358
|
3w5eA |
Crystal structure of phosphodiesterase 4b in complex with compound 31e |
|
137
|
331
|
3v9bA |
Crystal structure of the catalytic domain of pde4d2 with (s)-n-(3-{1-[1-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)-2-(1-oxypyridin-4-yl)-ethyl]-1h-pyrazl-3-yl}phenyl)acetamide |
|
135
|
334
|
3tvxA |
The structure of pde4a with pentoxifylline at 2.84a resolution |
|
138
|
327
|
3sl3A |
Crystal structure of the apo form of the catalytic domain of pde4d2 |
|
136
|
327
|
3sl6A |
Crystal structure of the catalytic domain of pde4d2 with compound 12c |
|
139
|
327
|
3sl8A |
Crystal structure of the catalytic domain of pde4d2 with compound 10o |
|
137
|
329
|
3sl4A |
Crystal structure of the catalytic domain of pde4d2 with compound 10d |
|
133
|
328
|
3sl5A |
Crystal structure of the catalytic domain of pde4d2 complexed with compound 10d |
|
133
|
334
|
5wqaA |
Crystal structure of pde4d catalytic domain complexed with selaginpulvilins k |
|
137
|
326
|
5wh6A |
Crystal structure of pde4d2 in complex with inhibitor (s_zl-n-91) |
|
137
|
326
|
5wh5A |
Crystal structure of the pde4d2 catalytic domain in complex with inhibitor (r)-zl-n-91 |
|
137
|
329
|
5tkbA |
Crystal structure of human phosphodiesterase 4d in complex with a tetrafluoranline compound |
|
135
|
336
|
5ohjA |
Human phosphodiesterase 4b catalytic domain in complex with a pyrrolidinyl inhibitor. |
|
140
|
330
|
5lboA |
Crystal structure of human phosphodiesterase 4d2 catalytic domain with inhibitor npd-001 |
|
138
|
337
|
5laqA |
Crystal structure of human phosphodiesterase 4b catalytic domain with inhibitor npd-001 |
|
128
|
324
|
5k32A |
Pde4d crystal structure in complex with small molecule inhibitor |
|
138
|
318
|
4y2bA |
Co-crystal structure of 3-ethyl-2-(isopropylamino)-7-(pyridin-3-yl)thieno[3,2-d]pyrimidin-4(3h)-one bound to pde7a |
|
130
|
347
|
4wcuA |
Pde4 complexed with inhibitor |
|
171
|
492
|
4wziA |
Crystal structure of crosslink stabilized long-form pde4b |
|
131
|
322
|
4w1oA |
Pde4d complexed with inhibitor |
|
166
|
492
|
4x0fA |
Crystal structure of crosslink stabilized long-form pde4b in complex with (r)-(-)-rolipram |
|
137
|
318
|
4pm0A |
Pde7a catalytic domain in complex with 2-(cyclopentylamino)thieno[3,2-d]pyrimidin-4(3h)-one derivative |
|
134
|
328
|
4ogbA |
Crystal structure of the catalytic domain of pde4d2 with compound 2 |
|
139
|
359
|
4nw7A |
Pde4 catalytic domain |
|
142
|
357
|
4myqA |
Selective inhibition of the catalytic domain of human phosphodiesterase 4b with a-33 |
|
141
|
324
|
4kp6A |
Crystal structure of human phosphodiesterase 4b (pde4b) in complex with a [1,3,5]triazine derivative |
|
137
|
323
|
3o0jA |
Pde4b in complex with ligand an2898 |
|
138
|
335
|
3o56A |
Catalytic domain of human phosphodiesterase 4b2b in complex with a 5-heterocycle pyrazolopyridine inhibitor |
|
142
|
336
|
3o57A |
Catalytic domain of human phosphodiesterase 4b2b in complex with a 5-heterocycle pyrazolopyridine inhibitor |
|
139
|
345
|
3ly2A |
Catalytic domain of human phosphodiesterase 4b in complex with a coumarin-based inhibitor |
|
128
|
347
|
3kktA |
Crystal structure of human pde4b with 5-[3-[(1s,2s,4r)-bicyclo[2.2.1]hept-2-yloxy]-4-methoxyp henyl]tetrahydro-2(1h)-pyrimidinone reveals ordering of the c-terminal helix residues 502-509. |
|
136
|
329
|
3k4sA |
The structure of the catalytic domain of human pde4d with 4-(3-butoxy-4-methoxyphenyl)methyl-2-imidazolidone |
|
130
|
325
|
3iakA |
Crystal structure of human phosphodiesterase 4d (pde4d) with papaverine. |
|
89
|
295
|
3ib7A |
Crystal structure of full length rv0805 |
|
138
|
358
|
3iadA |
Crystal structure of human phosphodiesterase 4d with bound allosteric modulator |
|
90
|
295
|
3ib8A |
Crystal structure of full length rv0805 in complex with 5'-amp |
|
131
|
335
|
3i8vA |
Crystal structure of human pde4a with 4-(3-butoxy-4-methoxyphenyl)methyl-2-imidazolidone |
|
139
|
360
|
3hmvA |
Catalytic domain of human phosphodiesterase 4b2b in complex with a tetrahydrobenzothiophene inhibitor |
|
131
|
324
|
3hc8A |
Investigation of aminopyridiopyrazinones as pde5 inhibitors: evaluation of modifications to the central ring system. |
|
129
|
323
|
3hdzA |
Identification, synthesis, and sar of amino substituted pyrido[3,2b]pryaziones as potent and selective pde5 inhibitors |
|
139
|
336
|
3gwtA |
Catalytic domain of human phosphodiesterase 4b2b in complex with a quinoline inhibitor |
